Sera Prognostics Inc - Asset Resilience Ratio
Sera Prognostics Inc (SERA) has an Asset Resilience Ratio of 46.21% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check SERA strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Sera Prognostics Inc's Asset Resilience Ratio has changed over time. See Sera Prognostics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Sera Prognostics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sera Prognostics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $43.23 Million | 46.21% |
| Total Liquid Assets | $43.23 Million | 46.21% |
Asset Resilience Insights
- Very High Liquidity: Sera Prognostics Inc maintains exceptional liquid asset reserves at 46.21% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sera Prognostics Inc Industry Peers by Asset Resilience Ratio
Compare Sera Prognostics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Sera Prognostics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Sera Prognostics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.59% | $35.26 Million | $101.93 Million | -23.55pp |
| 2024-12-31 | 58.14% | $42.19 Million | $72.58 Million | +10.78pp |
| 2023-12-31 | 47.36% | $45.20 Million | $95.44 Million | +1.95pp |
| 2022-12-31 | 45.41% | $52.83 Million | $116.33 Million | +14.00pp |
| 2021-12-31 | 31.41% | $46.18 Million | $147.03 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $14.80 Million | -- |
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of… Read more